Get started

TA

Price at support level of Bull flag trend line. 1 hour Chart. Looking at the 1 hour chart, price action seems to be holding at the bottom trend line of what appears to be the formation of a bull flag. Volume has decreased significantly as compared to the recent pump, signaling another move in the near future. I'm waiting to see if it's going to pump to higher ground or retest the bottom of the upper sloping channel, or possibly testing the 200 day EMA. Only time will tell.
BITSTAMP:ETHUSDLong
by russellcmaxwell
2
Looking for a DOGEUSDT Long at the 22c levelHighlighted area of interest for DOGE after this little mini pump. See it aligns well with our golden pocket and Gravytrain cloud. I always draw my fibs at the first bullish candle of the move and look for that fib zone, where price will often consolidate before the next move up. Happy to be right, happy to the wrong as we learn from our mistakes, but this is where i'll play on DOGE - May the trades be forever in your favour **Would love to know your thoughts or charts below!
by Unity-Trading-Group
Swipe SXP poised for a bull run!A bullish Navarro200 harmonic is presented and a deep retracement to the first higher low. Then, another higher low with another deep retracement (after what looks like a possible bullish deep crab on the 4hr) leading to the next higher low. An entry could have been made on the 2nd low, but there is plenty of upside still if it can get above $2.57ish where there some resistance. To sweeten the deal, there is hidden bullish divergence on BOTH the MACD and RSI. I also like the fact that higher lows have been made ever since Dec of 2019. Its very possible to see the price reach up near A of the harmonic if resistances can become support!
BINANCE:SXPUSDLong
by house_md74
Top Crypto Influencers To Follow In 2021(🔴PART 2)Hi guys As I promised in the previous post about influencers, I also posted the second part for you, there are 6 other people on my list, and if the number of likes reaches 270, I will post it for you as well. ✨1.Loomdart(@loomdart) Loomdart is a cryptocurrency analyst and veteran trader who has been actively dishing out well-researched, pertinent trading and investment tips and strategies on Twitter since mid-2014. ✨2.Starbust(@cryptostardust) Also known as Inversebrah in the crypto community, Starbust can only best perfectly described a crypto memes connoisseur. Much to the amusement of his thousands of followers, Starbust's online persona brings a satirical and comical twist to the often over-serious and overcomplicated debate on cryptocurrencies and his popularity is only rising, so you might want to follow him to a laugh or two ✨3.Lil Bubble(@TheCryptoBubble) Popularly known for producing parody versions of famous songs by the likes of Blink 182 and Avil Lavigne, Lil Bubble is undoubtedly the biggest satirist in the cryptocurrency space with hits like All Time Lows and Liquidated pushing him into an bigger online stardom. His productions can be found on Instagram and Twitter. ✨4.Altcoin Sara(www.youtube.com) Sara is a rare female face in the crypto space and one of the community’s biggest advocates through initiatives like the Altcoin Buzz Ladies YouTube channel, where she discusses cryptocurrency news, provides market analysis and offers a platform for alternative perspectives in the world of blockchain. ✨5.Credible Crypto Your main stop for understanding crypto trades, trends, and the marketplace at large is none other than Credible Crypto. Through his relentless quips on Twitter, Credible Crypto shares market analysis and investing advice with a healthy dose of humor thrown into the mix. He also does a superb job at breaking down key concepts and delivering a simple and approachable strategy to crypto investments and business ✨6.Changpeng Zhao(@cz_binance) More commonly known as "CZ", this business executive is none other than the founder and CEO of the world's largest cryptocurrency exchange - Binance. With an impressive track record in software development and trading for Bloomberg, CZ also found success while working at Blockchain.info before moving on to found his own startup. He frequently shares his wealth of knowledge on Twitter, earning him a solid spot on this list of crypto influencers. ✨7.Nicholas Merten(@Nicholas_Merten) Nicholas Merten is the founder of DataDash, the largest and arguably one of the most influential YouTube channels solely dedicated to covering crypto-related news. He's equally active on Twitter. ✨8.Roger Ver(@rogerkver) Another early investor, Ver has supported a number of cryptocurrency startups and projects over the years, cementing his status as 'Bitcoin Jesus' (as he likes to proclaim himself). He's also a leading digital philanthropist after major donations toward economic education. He currently serves as CEO of Bitcoin.com and you can find him Twitter. ✨9.Vitalik Buterin(@VitalikButerin) The co-founder of Ethereum (and the world’s youngest known crypto billionaire), boasts a massive online following, in large part due to his outspoken and opinionative views. The Canadian-Russian programmer isn’t exactly shy when it comes to stoking debate over some of the crypto industry’s most controversial aspects and has been praised for tackling sensitive issues head-on. He uses his platform to put pragmatism and principles before crypto politics. Buterin has also become a leading crypto philanthropist, making hefty donations to major causes. Follow him on Twitter, where he tends to drop some pretty big announcements. ✨10.Gavin Andresen(@gavinandresen) Primarily known for his crucial contribution toward developing Bitcoin during its initial phase, Gavin Andresen was considered Satoshi Nakamoto’s right-hand man, taking over from the Bitcoin founder after his abrupt departure from the project in 2010. Andersen then went on to become the face for Bitcoin as it exploded into mainstream consciousness. He’s since gone into semi-retirement but still plays a big and influential role as Chief Scientist at the Bitcoin Foundation. You can find him on Twitter.
BITSTAMP:BTCUSDEducation
by seyed_mehdi
ETHvs BTC - BinanceENGLISH ETherium vs bitcoin is bullish tinged. Very nice price action currently on display Trading ranges indicate to us that we are on support and moving towards initial resistance around and around the EQ and main purpose here on the daily is trading range resistance suits around 92000 sats ish. we also leave the double trading range bands (strong signal). OBs also indicate here that we are on support, Suds is not a zone of many conflicts here, 50/50 bear/bull. I will take this out of our game plan for a moment. Momentum low also indicates buy, only the slope of the green band is horizontally to slightly down debilitating, favoring the bulls so with some vigilance (due to the tires of the momentum meter). Paternwise has a high chance of a bull flag/pennat brake out, here is the key zone for attachment 79900-80000 sats zone, close above it imo the ignition is up to a massive run. and then as a last layer we use the VPVR, again, confirmation of a thick and important zone, where we find ourselves in 1 of the larger volume nodes currently as support also acting. Given the data layers us continue to guide in the bullish direction, our game plan is next. *no financial advice and always dyor DUTCH ETherium vs bitcoin is bullish getint. Zeer mooie prijsactie momenteel te zien Trading ranges geven ons aan dat we op steun zitten en vertrekkende richting eerste weerstand om en rond het EQ en hoofddoel hier op de daily is trading range weerstand pakken rond 92000 sats ish. ook verlaten we de dubbel trading range banden (sterk signaal). OBs geven ook hier aan dat we op steun zitten, Suds geen hier een zone aan van veel conflicten, 50/50 bear/bull. deze neem ik dan ook even buiten beschouwing in ons gameplan. Momentum laag geeft ook hier buy aan, enkel nog de slope van de groene band is horizontaal tot lichtjes down slopend, favoring the bulls dus met enige waakzaamheid (ivm de banden van de momentum meter). Paternwise een hoge kans op een bull flag /pennat brake out, hier is de key zone voor bevestiging 79900-80000 sats zone, close erboven is imo de ontsteking tot een massive run. en dan als laatste laag gebruiken we de VPVR, ook hier bevestiging van een dikke en belangrijke zone, waar we ons bevinden in 1 van de grotere volume nodes momenteel als steun ook fungerend. Gezien de data lagen ons blijven gidsen in de bullish richting is ons gameplan volgende. *no financial advice and always dyor
Long
by MyPileus
AVAXbtc - BinanceAVAX vs bitcoin ENGLISH yes man, nice price action, solid in uptrending. so picking up this guy is not an easy job. Nevertheless, we manage to find a nice and safe setup in my eyes. We are filled is of course the question, but when we are filled there I am quite satisfied to do it on our first and 2nd zone. Do you want to know how I get there? Do watch the live TA video via the link below. subscribe to our trading view channel here and give it a thumbs up. Thanks for the little effort that makes a world of difference to us :-). Keep you good and strong and until the next DUCTH ja man, mooie prijsactie, stevig in uptrending. dus deze jongen oppakken is geen gemakkelijke job. Toch slagen we er in om een mooie en safe setup te vinden in mijn ogen. Worden we gevuld is natuurlijk de vraag, maar als we daar gevuld worden ben ik best wel tevreden om het op onze eerste en 2de zone te doen. Wil je weten hoe ik er aan kom? Wel kijk naar de live TA video via de link hier onder. abonneer je hier op ons tradingview kanaal en geef het een duimpje up. Thanks voor de kleine moeite die een wereld van verschil maakt voor ons :-). Hou je jullie goed en sterk en tot de volgende
Long
by MyPileus
LINKusdt - BinanceENGLISH Link is one of them to me. Big big accumulation period, resulting from a solid uptrending. but for now (and actually for a while) the steam seems to be off. Momentum is hinting down on the 3d tf, and we also have local lower lows. Not really what you want/can see in a bull structure. s always, we're going to try to pick up Link as low and safe as possible. Paternwise we get a hinting that we can go lower, and we see quite a few confluneces lower. Watch the full video to understand everything and create your self. E: 13.86 and the box from 10-8 dollars S: 7.05 Tp 23.57 - 30.57 - 40.72 - 44.13 - 53.08 *This is not financial advice, always do your own research and trade safe. To know more, contact us via Tradingview - telegram or our site. DUTCH Link is er me eentje. Big big accumulatie periode, gevolg door een stevig uptrending. maar voor nu ( en eigenlijk al een tijdje) lijkt de stoom er af te zijn. Momentum is hinting down op de 3d tf, en we hebben ook lokale lower lows. niet echt wat je wil/kan zien in een bull structuur. Zoals altijd gaan we proberen om zo laag en veilig mogelijk Link op te pikken. Paternwise krijgen we een hinting dat we lager kunnen gaan, en we zien nogal wat confluneces lager. Bekijk de volledige video om alles te begrijpen en je zelf te educeren. E: 13.86 en de box van 10 - 8 dollar S: 7.05 Tp 23.57 - 30.57 - 40.72 - 44.13 - 53.08 *Dit is geen financieel advies, doe steeds je eigen onderzoek en trade safe. Meer weten, contacteer ons via Tradingview - telegram of onze site.
Long
by MyPileus
BEL vs BTC - BinanceBella protocol. ENGLISH Bella protocol. Were seeing on the graph We see on this chart a nice number of patterns playing out this especially hinting in the bullish zone. A double bottom, a rising channel and a larger ascending triangle, all in a premature state, but that's just what we need to enter safely. Better to get in early and see it evolve with a feeling of letting it sink in and rising we are low enough in that to want to enter the sharp of the cut all the time. You can only harvest when you sow ;-). Therefore, safe long setup E: 4178 S: 3214 T: 5429 - 6289 - 6961 - 8315 - 10006 DUTCH Were seeing on the graph We zien op deze grafiek een mooi aantal patronen uitspelen dit vooral hinten in de bullish zone. Een double bodem, een rising channel en een grotere ascending triangle, allen in een premature staat, maar dat is net wat we nodig hebben om safe te enteren. Beter vroeg erin en zien evolueren met een gevoel van laat maar even zakken en stijgen we zitten er laag genoeg in dat om het scherp van de snede steeds te willen enteren. Je kunt pas oogsten als je zaait ;-). Daarom, safe long setup E: 4178 S: 3214 T: 5429 - 6289 - 6961 - 8315 - 10006
Long
by MyPileus
2
$LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - Additional data presented today showed responses to treatment are independent of PD-L1 expression, with 79% ORR in patients with PD-L1 low (CPS < 5) tumors - Company to host conference call on Friday, September 17, 2021 at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study. The Company announced positive initial data from the DisTinGuish study on Monday, September 13, 2021 based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity. The results presented at the ESMO Congress today included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression. "Initial data from this trial have shown that patients with high levels of DKK1 expression, a group with a poor prognosis, had encouraging responses to treatment. The additional data presented today show evidence that not only is DKK1 a critical biomarker in predicting response to DKN-01 and tislelizumab therapy, but also that the combination can induce deep responses regardless of the patient's PD-L1 status, including particularly poor prognosis patients with both low PD-L1 and high DKK1," said Samuel Klempner, MD, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School. "Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers." About the DisTinGuish Study The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study will enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Key Findings Among patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in DKK1-high patients and 56% in DKK1-low patients Response was independent of PD-L1 expression, and particularly strong in the less favorable to checkpoint inhibitor therapy, PD-L1 low (vCPS < 5), population DKK1 expression and PD-L1 expression are not correlated Median duration of response and progression-free survival data are not yet mature, and patient follow-up continues Twenty-five first-line patients were enrolled, and as of the cut-off date of the presentation, 15 patients had experienced a partial response (PR), six patients had a best response of stable disease (SD), one patient was non-evaluable for response (NE), and three patients were unable to complete a full cycle of DKN-01 therapy (non-modified ITT (mITT)). Among the 21 patients that had RNAscope® DKK1 expression available, 12 were DKK1-high and 9 were DKK1-low . Among the 20 patients that had PD-L1 expression available, 14 were PD-L1 low vCPS < 5 and 6 were PD-L1 high vCPS > 5 . A copy of the poster presentation is available on the Company's website at www.leaptx.com Conference Call Leap will host a conference call on Friday, September 17, 2021 at 8:00 a.m. Eastern Time to further discuss the data. In addition to Leap's executive management team, Dr. Jaffer Ajani of M.D. Anderson Cancer Center and Dr. Samuel Klempner of Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 1729397. The presentation will be webcast live and may be accessed on the Investors page of the Company's website at investors.leaptx.com where a replay of the event will also be available for a limited time. About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
NASDAQ:LPTXLong
by BADQOMOCAWGOWLD
1